NFSG
ACAD icon

Newbridge Financial Services Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Newbridge Financial Services Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-70
Closed -$1.46K – 1121
2023
Q3 		$1.46K Hold
70
– – ﹤0.01% 1119
2023
Q2 		$1.68K Hold
70
– – ﹤0.01% 1157
2023
Q1 		$1.32K Hold
70
– – ﹤0.01% 1251
2022
Q4 		$1.11K Hold
70
– – ﹤0.01% 1289
2022
Q3 		$1K Hold
70
– – ﹤0.01% 1263
2022
Q2 		$1K Hold
70
– – ﹤0.01% 1242
2022
Q1 		$2K Hold
70
– – ﹤0.01% 1260
2021
Q4 		$2K Sell
70
-150
-68% -$3.02K ﹤0.01% 1208
2021
Q3 		$4K Sell
220
-150
-41% -$2.89K ﹤0.01% 1037
2021
Q2 		$9K Hold
370
– – 0.01% 999
2021
Q1 		$10K Buy
370
+70
+23% +$3.08K 0.01% 888
2020
Q4 		$16K Hold
300
– – 0.01% 592
2020
Q3 		$12K Buy
+300
New +$13K 0.01% 620

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Newbridge Financial Services Group's ACAD Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 70 shares — an estimated $1.46K sold.

Newbridge Financial Services Group first reported a position in ACAD in Q3 2020 and held it in 13 quarters. The position peaked at $16K in Q4 2020. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 70 Acadia Pharmaceuticals shares in Q4 2023, an estimated $1.46K.
  • Newbridge Financial Services Group first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 13 quarters.
  • Newbridge Financial Services Group's Acadia Pharmaceuticals position peaked at $16K in Q4 2020.
  • 276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.